Daniel S. Clevenger

Representative Experience

• Represented Novellus Therapeutics, a developer of novel medicines intended for the treatment of pediatric disease, in its sale to Brooklyn ImmunoTherapeutics (NYSE: BTX) for $125 million 
• Represented computer-aided engineering company Exa Corporation (Nasdaq :EXA) in its $400M sale to French software company Dassault. 
• Represented Living Proof, Inc. in its acquisition by Unilever.
• Represented Applied Genetic Technologies Corporation, a Florida-based biotechnology company, in its initial public offering and subsequent follow-on offering.
• Represented Hittite Corporation in its sale to Analog Devices, Inc.
• Represented lead investor in $75 million Series B financing of a pharmaceuticals company.
• Represented a healthcare information management company and its equity holders in $68.5 million sale to a strategic buyer.
• Represented Exa Corporation, a Massachusetts-based provider of software simulation tools, in its initial public offering.
• Represented Art Technology Group, a provider of e-commerce software, in its $1.0 billion sale to Oracle Corporation.
• Represented lead investor in $55 million investment in development stage biopharmaceutical company.
• Represented Alere Inc., NYSE-listed medical device manufacturer, in private and public offerings of debt securities with an aggregate principal amount of $1.05 billion.